Short ragweed pollen allergen extract - Biologic Drug Details

Summary for short ragweed pollen allergen extract

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1

Pharmacology for short ragweed pollen allergen extract

Physiological Effect	Cell-mediated Immunity Increased Histamine Release Increased IgG Production
Established Pharmacologic Class	Standardized Pollen Allergenic Extract
Chemical Structure	Allergens Pollen

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for short ragweed pollen allergen extract Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for short ragweed pollen allergen extract Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for short ragweed pollen allergen extract Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory of Short Ragweed Pollen Allergen Extract

Last updated: July 27, 2025

Introduction to Short Ragweed Pollen Allergen Extract

Short ragweed pollen allergen extract, commonly known by its brand name Ragwitek, is a biologic drug used in immunotherapy for the treatment of short ragweed pollen-induced allergic rhinitis. This innovative treatment has gained significant traction in the allergy immunotherapy market, offering hope to millions suffering from ragweed allergies.

The Growing Allergy Immunotherapy Market

The global allergy immunotherapy market is experiencing robust growth, with short ragweed pollen allergen extract playing a crucial role. According to recent market analysis:

The global allergy immunotherapy market is anticipated to grow from $1.70 billion in 2023 to $4.02 billion by 2032, at a CAGR of 10.3%[1]

This impressive growth trajectory underscores the increasing demand for effective allergy treatments, including short ragweed pollen allergen extract.

Factors Driving Market Growth

Several factors are contributing to the expansion of the allergy immunotherapy market:

1. Rising prevalence of allergies
2. Increasing awareness about immunotherapy
3. Technological advancements in allergen extraction
4. Growing investment in research and development

Market Segmentation

The allergy immunotherapy market is segmented based on various factors:

By Indication

• Allergic rhinitis
• Allergic asthma
• Others (including food allergies and insect allergies)

The allergic rhinitis segment dominates the market, with short ragweed pollen allergen extract playing a significant role in this category.

By Distribution Channel

• Hospital pharmacies
• Retail and online pharmacies

Retail and online pharmacies lead the market share due to convenience and special discounts offered.

Short Ragweed Pollen Allergen Extract: Market Position

Short ragweed pollen allergen extract, particularly Ragwitek, has established a strong position in the allergy immunotherapy market. As the first FDA-approved sublingual allergen immunotherapy tablet for short ragweed pollen allergies, it has gained significant market share.

Key Players in the Market

The market for short ragweed pollen allergen extract is semi-consolidated, with a few key players dominating:

1. ALK-Abello
2. Stallergenes Greer
3. Allergy Therapeutics
4. Merck & Co. (manufacturer of Ragwitek)

ALK-Abello holds the lion's share of the market, thanks to its strong presence and robust product portfolio.

Competitive Strategies

Companies in this space are employing various strategies to maintain and expand their market share:

• Investing in research and development
• Expanding geographical presence
• Focusing on personalized immunotherapy
• Engaging in strategic collaborations and partnerships

Financial Trajectory of Short Ragweed Pollen Allergen Extract

The financial trajectory of short ragweed pollen allergen extract is closely tied to the overall growth of the allergy immunotherapy market. While specific revenue figures for this product are not publicly available, we can infer its financial performance based on market trends and company reports.

Market Value and Growth Projections

The allergic rhinitis segment, where short ragweed pollen allergen extract primarily operates, is expected to witness significant growth. This growth is driven by:

• Increasing burden of allergic rhinitis cases
• Launch of new products by key players
• Strong pipeline of products focused on allergic rhinitis treatment

Regional Market Dynamics

The market for short ragweed pollen allergen extract varies by region:

North America

North America is anticipated to observe considerable growth during the forecast period. Factors contributing to this growth include:

• Rise in treatment rates
• Increased adoption of novel allergy immunotherapy
• Rising cases of allergies

Europe

Europe, particularly countries with high ragweed pollen prevalence, represents a significant market for short ragweed pollen allergen extract.

Asia Pacific

The Asia Pacific region is expected to grow at the highest CAGR during the forecast period, driven by:

• Rising burden of allergy patients
• Increasing focus of key players on expanding their presence
• Growing awareness about allergy management

Regulatory Landscape and Its Impact on Market Dynamics

The regulatory environment plays a crucial role in shaping the market for short ragweed pollen allergen extract. FDA approval and subsequent expansions of indications have significantly influenced the product's market penetration.

FDA Approval and Expanded Indications

Ragwitek, a key short ragweed pollen allergen extract product, has seen its market potential expand through regulatory approvals:

• Initially approved in 2014 for adults 18-65 years old
• In 2021, FDA expanded approval to include children and adolescents 5 years and older

This expanded approval has opened up a new demographic, potentially boosting sales and market share.

Safety Considerations and Their Market Impact

While effective, short ragweed pollen allergen extract products come with important safety considerations. The FDA requires a boxed warning for potential severe allergic reactions, including anaphylaxis. This necessitates:

• Initial dose administration under medical supervision
• Prescription of auto-injectable epinephrine
• Patient education on proper use

These safety requirements, while crucial, may impact the product's accessibility and, consequently, its market penetration.

Innovation and Product Development

Continued innovation in short ragweed pollen allergen extract products is crucial for maintaining market growth and competitiveness.

Current Product Offerings

The current market leader, Ragwitek, offers:

• Sublingual tablet formulation
• 12 Amb a 1-Unit dosage
• Once-daily dosing regimen

Future Directions in Product Development

Future innovations in this space may focus on:

1. Improved efficacy and safety profiles
2. Novel delivery methods
3. Combination therapies addressing multiple allergens
4. Personalized immunotherapy approaches

Market Challenges and Opportunities

While the market for short ragweed pollen allergen extract shows promising growth, it also faces several challenges and opportunities.

Challenges

1. Safety concerns and risk of severe allergic reactions
2. High cost of treatment
3. Long treatment duration (typically starts 12 weeks before ragweed season)
4. Competition from symptomatic treatments and other immunotherapy approaches

Opportunities

1. Expanding indications to younger age groups
2. Increasing prevalence of ragweed allergies due to climate change
3. Growing demand for non-invasive treatment options
4. Potential for combination therapies addressing multiple allergens

The Impact of Climate Change on Market Dynamics

Climate change is having a significant impact on the prevalence and distribution of ragweed pollen, consequently affecting the market for short ragweed pollen allergen extract.

When applying a management regime that uses 50 MEUs (15 million € per year) annually, the mean allergy costs drop to 82 million € per year[8]

This statistic highlights the potential economic impact of ragweed management, indirectly affecting the market for allergen extracts.

Expanding Ragweed Distribution

Climate change is facilitating the spread of ragweed to new geographical areas, potentially expanding the market for short ragweed pollen allergen extract products.

Longer Pollen Seasons

Warmer temperatures are leading to longer ragweed pollen seasons, potentially increasing the demand for year-round allergy management solutions.

The Role of Patient Education and Awareness

Patient education and awareness play a crucial role in driving the adoption of short ragweed pollen allergen extract treatments.

Importance of Allergy Diagnosis

Proper diagnosis of ragweed allergies is crucial for appropriate treatment. As noted in the FDA approval:

Ragwitek is an allergen extract indicated for the treatment of short ragweed pollen-induced allergic rhinitis, with or without conjunctivitis, confirmed by positive skin test or in vitro testing for pollen-specific IgE antibodies for short ragweed pollen in adults 18 to 65 years of age[5]

Increasing awareness about the importance of proper allergy diagnosis can drive market growth.

Understanding Treatment Options

Educating patients about the benefits of immunotherapy over symptomatic treatments can increase adoption rates of short ragweed pollen allergen extract products.

Future Market Outlook

The future market outlook for short ragweed pollen allergen extract remains positive, driven by several factors:

1. Increasing prevalence of ragweed allergies
2. Expanding indications and patient populations
3. Ongoing research and development efforts
4. Growing awareness about immunotherapy benefits

As the market continues to evolve, we can expect to see continued innovation, potential new market entrants, and possibly, consolidation among existing players.

Key Takeaways

1. The global allergy immunotherapy market is growing rapidly, with a projected CAGR of 10.3% from 2023 to 2032.
2. Short ragweed pollen allergen extract, particularly Ragwitek, holds a significant position in this market.
3. Regulatory approvals, including expanded indications, have boosted market potential.
4. Climate change is indirectly driving market growth by expanding ragweed distribution and lengthening pollen seasons.
5. Patient education and proper diagnosis are crucial for market expansion.
6. Despite challenges like safety concerns and high treatment costs, the future outlook remains positive, driven by increasing allergy prevalence and ongoing innovation.

FAQs

1. What is short ragweed pollen allergen extract? Short ragweed pollen allergen extract is a biologic drug used in immunotherapy for treating allergies caused by short ragweed pollen.

2. How big is the market for allergy immunotherapy? The global allergy immunotherapy market is expected to grow from $1.70 billion in 2023 to $4.02 billion by 2032.

3. What factors are driving the growth of this market? Key drivers include rising allergy prevalence, increasing awareness about immunotherapy, technological advancements, and growing R&D investments.

4. How does climate change affect the market for short ragweed pollen allergen extract? Climate change is expanding ragweed distribution and lengthening pollen seasons, potentially increasing demand for related allergy treatments.

5. What are the main challenges facing this market? Major challenges include safety concerns, high treatment costs, long treatment duration, and competition from alternative treatments.

Sources cited: [1] https://www.fortunebusinessinsights.com/industry-reports/allergy-immunotherapy-market-100727 [5] https://www.mayoclinic.org/drugs-supplements/short-ragweed-pollen-allergen-extract-sublingual-route/description/drg-20095270 [8] https://besjournals.onlinelibrary.wiley.com/doi/10.1111/1365-2664.12156